Bioidentical Hormone Replacement Therapy for Women: Why Estrogen, Progesterone, and Testosterone Matter
Most women do not walk into our clinic saying, “My estradiol is low and my progesterone and testosterone need to be optimized.”
They say things like:
“I don't feel like myself anymore.”
“I can't sleep.”
“I've completely lost my sex drive.”
“I am gaining weight even though I haven't changed what I'm doing.”
“My workouts don't work like they used to.”
“My brain feels foggy.”
“My joints hurt.”
“I feel anxious for no reason.”
“Sex is uncomfortable.”
“I am exhausted all the time.”
“My doctor checked my hormones and told me everything was normal.”
These symptoms are often treated individually. Insomnia may lead to a sleep medication. Anxiety may lead to an antidepressant. Vaginal dryness may lead to a vaginal cream. Weight gain may lead to a diet. Low libido may simply be dismissed as part of getting older.
Sometimes those treatments are appropriate.
But sometimes they miss a much bigger question:
What happened to the hormones that helped regulate these systems before the symptoms began?
For many women in their 40s, 50s, and beyond, declining or fluctuating estrogen, progesterone, and testosterone are not isolated reproductive events. Sex hormones influence the brain, bones, muscles, cardiovascular system, vaginal and urinary tissues, metabolism, sleep, sexual function, connective tissue, and quality of life.
That is why our approach to bioidentical hormone replacement therapy, or BHRT, is different from simply treating one menopausal symptom at a time.
The goal is not merely to stop a hot flash.
The goal is to evaluate whether hormone loss is contributing to declining function and, when appropriate, restore hormones toward healthy physiologic premenopausal ranges using hormones that are structurally identical to those the woman's body naturally produced.
That distinction changes the entire conversation.
Menopause Is More Than the End of Menstrual Periods
Menopause is typically defined retrospectively after a woman has gone 12 consecutive months without a menstrual period.
But the hormonal transition begins well before that point.
During perimenopause, ovarian function becomes increasingly inconsistent. Ovulation may occur one month and not the next. Progesterone can decline or fluctuate because progesterone production depends heavily on ovulation. Estradiol may swing dramatically before ultimately trending downward.
Testosterone and other androgens also change across adulthood.
The result is that a woman can have meaningful hormonal symptoms long before her periods stop completely.
Symptoms associated with the menopausal transition can include:
-
hot flashes
-
night sweats
-
insomnia
-
waking during the night
-
anxiety
-
irritability
-
mood changes
-
declining concentration
-
brain fog
-
memory complaints
-
fatigue
-
loss of sexual interest
-
vaginal dryness
-
painful intercourse
-
urinary symptoms
-
changes in body composition
-
declining muscle mass
-
increasing abdominal fat
-
declining exercise recovery
-
headaches
-
joint discomfort
-
loss of skin elasticity
-
bone loss
This is why we should not ask only, “Has she reached menopause?”
We should ask:
“Is declining hormonal function contributing to the changes she is experiencing?”
What Does “Bioidentical” Actually Mean?
A bioidentical hormone has the same molecular structure as the hormone naturally produced by the human body.
For women's hormone replacement, three important examples are:
Estradiol, the primary and most potent estrogen during the reproductive years.
Progesterone, the same progesterone naturally produced primarily by the ovaries after ovulation.
Testosterone, an essential androgen naturally present in women as well as men.
Bioidentical hormone therapy should not be confused with the idea that all compounded products are automatically superior or that anything labeled “natural” is inherently safe.
The important point is molecular identity.
Estradiol is not the same molecule as conjugated equine estrogens.
Progesterone is not the same thing as medroxyprogesterone acetate or other synthetic progestins.
Those differences matter because different molecules can produce different effects at receptors, in the liver, in breast tissue, in the vascular system, and throughout the body.
The E3N studies are particularly instructive. In the French cohort, breast-cancer associations differed substantially depending on which progesterone-like compound accompanied estrogen. Estrogen combined with micronized progesterone showed a markedly different risk pattern from estrogen combined with many synthetic progestins.
This is exactly why it is inaccurate to discuss all “estrogen plus progesterone” therapies as though they were pharmacologically identical.
They are not.
Our Goal Is Restoration, Not Merely Symptom Suppression
There are two fundamentally different ways to approach menopausal hormone decline.
One is symptom based.
A woman has vaginal dryness, so give her vaginal estrogen.
She has hot flashes, so give her something to suppress hot flashes.
She cannot sleep, so give her something for sleep.
There is nothing inherently wrong with targeted symptom treatment.
But functional and integrative medicine asks another question:
Why did all of these symptoms begin around the same biological transition?
If systemic estradiol has fallen substantially, treating only the vaginal tissue does not restore estradiol's effects elsewhere in the body.
If progesterone has disappeared because ovulation has stopped, correcting one symptom does not recreate progesterone's systemic physiology.
If testosterone has fallen and a woman has lost libido, lean mass, drive, or other androgen-related function, ignoring testosterone because it is considered a “male hormone” makes little physiological sense.
Our objective is therefore not simply to make laboratory values look good.
It is to combine:
-
symptoms
-
history
-
menstrual and menopausal status
-
physical findings
-
laboratory assessment
-
cardiovascular risk
-
breast health
-
bone health
-
metabolic health
-
thyroid function
-
lifestyle
-
body composition
-
patient goals
and determine whether restoring hormone physiology is appropriate.
Estrogen: Far More Than a Reproductive Hormone
Estrogen receptors are distributed throughout the body.
Estradiol influences tissues involving the:
-
brain
-
blood vessels
-
bones
-
skin
-
vagina
-
urinary system
-
breasts
-
reproductive tract
-
connective tissue
-
metabolism
This explains why estrogen loss can produce symptoms that initially seem unrelated.
A woman may think she has ten different problems when several of them appeared because the same hormone system changed.
When Should a Woman Consider Estrogen Replacement?
Classic clues of declining estrogen include:
Hot flashes and night sweats
These are the symptoms most commonly associated with menopause, but they are only part of the picture.
Vaginal dryness and painful intercourse
Estrogen is critical for maintaining the thickness, elasticity, lubrication, vascularity, and normal environment of vaginal tissues.
Recurrent urinary or genital symptoms
Declining estrogen changes the tissues of the vagina, vulva, urethra, and bladder.
Sleep disruption
Some women awaken because of night sweats, while others report deterioration in sleep even without obvious vasomotor symptoms.
Bone loss
One of estrogen's most important roles is maintaining the balance between bone formation and bone resorption.
When estrogen falls, bone turnover accelerates.
Randomized trials of transdermal estradiol have demonstrated preservation or improvement of bone mineral density in postmenopausal women. Even very-low-dose transdermal estradiol significantly improved lumbar-spine and hip bone-density outcomes compared with placebo in one randomized trial.
Cognitive and mood changes
Many women describe brain fog, loss of mental sharpness, difficulty concentrating, or changes in mood during the menopausal transition.
Hormone therapy should not be represented as a proven treatment for dementia. That is a much different claim.
But estrogen has extensive neurobiological effects, and the timing of estrogen exposure appears important when discussing the brain and vascular system.
Changes in body composition and metabolic health
Menopause commonly coincides with declining lean mass, increasing visceral fat, worsening insulin sensitivity, and changes in lipid metabolism.
These changes are multifactorial. Hormones are not the only explanation.
But declining ovarian hormones are part of the physiologic transition and should not be ignored.
Why We Prefer Transdermal Estradiol — and Do Not Use Oral Estrogen
This is one of the most important distinctions in our approach to women's hormone therapy:
We do not use oral estrogen as our preferred method of physiologic estrogen replacement.
The reason is not merely philosophical.
It is physiological.
When estrogen is swallowed, it travels through the gastrointestinal tract and portal circulation directly to the liver before reaching the systemic circulation.
This first-pass hepatic metabolism substantially changes estrogen's effects.
Oral estrogen can increase hepatic production of clotting factors and alters proteins such as sex hormone-binding globulin, triglycerides, inflammatory markers, and other liver-derived factors.
Transdermal estradiol avoids much of that first-pass hepatic exposure.
The ESTHER study demonstrated the clinical importance of this distinction.
Among postmenopausal women, oral estrogen was associated with a markedly increased risk of venous thromboembolism compared with nonuse, with an adjusted odds ratio of approximately 4.2. Transdermal estrogen, in contrast, was not associated with increased VTE risk in the study, with an odds ratio of approximately 0.9. Micronized progesterone was also not associated with a significant increase in thrombotic risk.
A large subsequent BMJ analysis similarly found excess VTE risk associated with oral hormone therapy while transdermal estradiol was not associated with the same excess risk.
This is not a minor difference in delivery.
Route matters.
When systemic estrogen replacement is appropriate, our preference is therefore non-oral bioidentical estradiol, most commonly through transdermal or other non-oral delivery strategies.
What About Vaginal Estrogen?
Vaginal estrogen is a valid and useful treatment.
For women with vaginal dryness, painful intercourse, recurrent urinary symptoms, vulvovaginal discomfort, or other manifestations of genitourinary estrogen deficiency, local estrogen can be extremely effective.
But there is an important distinction.
If a woman has an isolated vaginal problem and does not need systemic hormone restoration, local therapy may be entirely appropriate.
If, however, a woman has systemic estrogen deficiency with:
-
hot flashes
-
night sweats
-
bone loss
-
sleep changes
-
cognitive complaints
-
systemic symptoms
-
declining overall hormone function
then vaginal estrogen is addressing a local consequence of the deficiency.
It does not replace systemic estrogen physiology.
In that situation, simply treating the vaginal tissue can be analogous to treating one branch of the tree while ignoring what is happening at the root.
This is not an argument against vaginal estrogen.
It is an argument for recognizing what vaginal estrogen can and cannot accomplish.
We may use local therapy when appropriate, including in combination with systemic therapy when localized symptoms require additional support.
But our broader objective remains physiologic restoration when systemic hormone loss is the underlying problem.
Timing Matters: The “Window of Opportunity”
The cardiovascular discussion surrounding estrogen became distorted after early interpretations of the Women's Health Initiative.
One of the problems was treating all postmenopausal women as though starting hormone therapy immediately after menopause were physiologically equivalent to beginning it decades later.
It isn't.
The ELITE trial directly examined the timing hypothesis.
Women were stratified into those who were less than six years beyond menopause and those who were at least ten years beyond menopause. Estradiol slowed progression of carotid intima-media thickness in the early-postmenopause group but not in women who started therapy much later.
This does not mean estrogen should be prescribed as a universal cardiovascular drug.
It means timing changes physiology.
The vascular environment of a healthy 51-year-old who recently transitioned through menopause is not the same as that of a woman beginning estrogen for the first time decades after estrogen deficiency and atherosclerosis have progressed.
That distinction is critical when discussing the risks and benefits of hormone restoration.
The KEEPS Trial: Early Hormone Therapy and Physiologic Outcomes
The Kronos Early Estrogen Prevention Study—KEEPS—evaluated recently menopausal women and included a treatment arm using transdermal 17-beta estradiol plus micronized progesterone.
KEEPS did not demonstrate a reduction in the primary measure of atherosclerosis progression, but it provided valuable information about early menopausal hormone therapy.
Both hormone-treatment groups improved menopausal symptoms and maintained bone density, and researchers identified differences among therapies in areas including mood, sleep, sexual function, and other outcomes.
The lesson is not that hormones are magical.
The lesson is that the molecule, route, timing, patient, and physiologic context all matter.
Progesterone: Not a Synthetic Progestin
This distinction needs to be extremely clear.
When we are discussing physiologic BHRT, we are talking about bioidentical progesterone.
We are not using the word “progesterone” as shorthand for every synthetic progestin.
Progesterone and synthetic progestins are not interchangeable molecules.
That matters tremendously when interpreting older hormone studies.
For example, the Women's Health Initiative combination arm used:
conjugated equine estrogen + medroxyprogesterone acetate
That is not the same therapy as:
17-beta estradiol + bioidentical micronized progesterone.
Long-term WHI follow-up found that conjugated equine estrogen plus medroxyprogesterone acetate increased breast-cancer incidence compared with placebo. The estrogen-alone arm in women who had undergone hysterectomy, however, demonstrated lower breast-cancer incidence and breast-cancer mortality during extended follow-up.
Whatever one's interpretation of WHI, those findings make one point impossible to ignore:
The hormone combination matters.
The E3N Data: Progesterone and Progestins Are Not the Same
The French E3N cohort provides some of the most important evidence supporting this distinction.
In an analysis of more than 54,000 postmenopausal women, breast-cancer risk differed depending on the compound combined with estrogen.
The relative risk associated with estrogen plus synthetic progestins was approximately 1.4, while estrogen combined with micronized progesterone had a relative risk of approximately 0.9, which was not statistically elevated compared with nonusers in that analysis.
A later E3N analysis involving more than 80,000 postmenopausal women again found substantial differences:
-
estrogen + progesterone: RR approximately 1.00
-
estrogen + dydrogesterone: RR approximately 1.16
-
estrogen + other progestins: RR approximately 1.69
The investigators concluded that the choice of the progesterone component matters substantially.
These are observational data rather than randomized trials, so they should not be interpreted as proving that micronized progesterone eliminates breast-cancer risk.
But they strongly challenge the assumption that all progesterone-like compounds should be lumped together.
Why Women Need Progesterone
Progesterone does much more than support pregnancy.
Progesterone interacts with the central nervous system, breasts, uterus, bones, and other tissues.
For women who still have a uterus, adequate progesterone is particularly important when systemic estradiol is used because progesterone opposes excessive estrogen-driven endometrial proliferation.
But we also consider progesterone physiologically rather than viewing it merely as something added to “protect the uterus.”
Progesterone metabolites interact with GABA-A receptors, which helps explain progesterone's effects on calmness and sleep.
A systematic review and meta-analysis of randomized controlled trials found that micronized progesterone improved several sleep outcomes, with the strongest pooled evidence demonstrating improvement in sleep-onset latency. Most of the trials involved postmenopausal women.
This can be clinically important for the woman whose first major symptom of hormonal decline is:
“I suddenly can't sleep anymore.”
Progesterone During Perimenopause
Progesterone loss may begin before profound estrogen deficiency.
Why?
Because progesterone production depends primarily on ovulation.
As ovulation becomes inconsistent during perimenopause, progesterone exposure can decline or fluctuate even while estradiol may still be normal—or occasionally quite high.
This helps explain why some women in their 40s experience:
-
worsening sleep
-
anxiety
-
irritability
-
breast tenderness
-
heavier menstrual bleeding
-
irregular periods
-
premenstrual migraines
-
mood changes
before developing classic menopausal hot flashes.
A randomized trial of oral micronized progesterone in symptomatic perimenopausal women found improvements in perceived night sweats and sleep quality, although the trial did not meet every predefined vasomotor primary outcome.
This is another reason we evaluate the entire hormone pattern rather than waiting until estradiol becomes profoundly low.
Why Progesterone Alone Is Not Always the Answer
Another integrative principle is balance.
If estrogen is substantially deficient, simply giving increasingly larger amounts of progesterone is not necessarily restoring physiology.
Estrogen and progesterone normally function together.
Likewise, testosterone operates within an endocrine environment that includes estrogen, thyroid hormone, insulin, cortisol, DHEA, growth hormone, and other signaling systems.
Hormone optimization should therefore avoid the trap of treating every symptom by continually increasing one hormone.
The goal is to recreate a physiologic hormonal environment, not simply chase isolated numbers.
Testosterone Is a Female Hormone Too
One of the most persistent misconceptions in women's medicine is that estrogen and progesterone are “female hormones” while testosterone belongs to men.
Women make testosterone throughout their reproductive lives.
Testosterone contributes to female sexual function and has biological activity in:
-
the brain
-
muscle
-
bone
-
skin
-
reproductive tissues
Testosterone can act directly through androgen receptors and can also be converted locally into other hormones, including estradiol.
As women age, androgen physiology changes.
Some women experience declining:
-
sexual desire
-
arousal
-
motivation
-
muscle mass
-
physical performance
-
recovery
-
sense of well-being
These symptoms are not specific to testosterone deficiency, so they must be evaluated in context.
But testosterone should not be ignored simply because the patient is female.
The Strongest Evidence for Testosterone in Women: Sexual Function
The strongest randomized evidence for testosterone therapy in women involves hypoactive sexual desire disorder, particularly after menopause.
A major international consensus review based on randomized controlled trials concluded that testosterone administered in doses that approximate physiologic premenopausal female concentrations improves several domains of sexual function in postmenopausal women with HSDD, including desire, arousal, orgasmic function, pleasure, sexual responsiveness, and sexual distress.
That phrase is important:
physiologic premenopausal concentrations.
The goal is not to masculinize women.
The goal is not supraphysiologic testosterone.
The goal is restoration of normal female androgen physiology.
Testosterone Should Not Be Prescribed From a Lab Number Alone
This is another area where functional medicine can go wrong if it becomes too laboratory driven.
There is no single testosterone concentration that perfectly distinguishes women with and without sexual dysfunction.
Testosterone measurements in women are also technically more challenging because concentrations are much lower than in men.
The international consensus statement specifically notes that no circulating androgen cutoff reliably separates women with sexual dysfunction from those without it.
Therefore, treatment decisions should integrate:
-
symptoms
-
clinical history
-
sexual health
-
relationship factors
-
estradiol status
-
thyroid function
-
medications
-
metabolic health
-
androgen levels
-
treatment response
The laboratory result matters.
It simply does not replace the clinical picture.
Estrogen and Testosterone Should Not Be Viewed in Isolation
One of the most valuable principles in integrative hormone medicine is that hormones function as a network.
A woman can have apparently adequate total testosterone but very high sex hormone-binding globulin, leaving considerably less bioavailable hormone.
Oral estrogen can significantly raise SHBG through hepatic first-pass metabolism, which is another reason oral estrogen may complicate androgen physiology.
A woman may receive testosterone for low libido when the real problem is profound estrogen deficiency causing vaginal pain.
Another woman may receive progressively more estrogen when progesterone, thyroid function, sleep, insulin resistance, stress physiology, or another system is contributing to her symptoms.
This is why “one symptom, one prescription” is often inadequate.
Hormones communicate with each other.
What About Muscle, Body Composition, Energy, and Testosterone?
Women commonly ask whether testosterone can help them maintain muscle, improve energy, lose fat, and recover from exercise.
Biologically, androgens influence muscle and other tissues.
Clinically, however, we should distinguish biological plausibility and clinical experience from what has been definitively demonstrated in high-quality randomized trials.
The strongest evidence for testosterone therapy in women remains sexual dysfunction.
That does not mean testosterone has no physiological role elsewhere.
It means we should avoid promising outcomes that the evidence cannot yet guarantee.
Our approach is to restore appropriate female physiology when clinically indicated while continuing to address:
-
resistance training
-
adequate protein
-
insulin sensitivity
-
thyroid function
-
sleep
-
caloric intake
-
micronutrients
-
cardiovascular fitness
Hormones amplify physiology.
They do not replace the fundamentals of physiology.
HRT and Breast Cancer: The Conversation Requires Precision
Few topics in women's medicine have generated more fear than estrogen and breast cancer.
The most important thing to understand is that “HRT” is not one treatment.
Compare these regimens:
-
conjugated equine estrogen
-
oral estradiol
-
transdermal 17-beta estradiol
-
estradiol pellets
-
estradiol plus medroxyprogesterone acetate
-
estradiol plus micronized progesterone
Calling all of these “HRT” and assuming identical risks is scientifically crude.
The WHI itself illustrates the problem.
Long-term follow-up demonstrated lower breast-cancer incidence and mortality in women randomized to conjugated equine estrogen alone after hysterectomy, while the combination of conjugated equine estrogen plus medroxyprogesterone acetate increased breast-cancer incidence.
Meanwhile, the E3N cohort demonstrated substantially different breast-cancer associations depending on whether estrogen was combined with micronized progesterone or synthetic progestins.
No responsible clinician should tell a woman that hormone therapy has zero risk.
But it is equally misleading to tell her that every estrogen molecule, every route, and every progesterone-like compound carries the same risk.
They do not.
HRT and Cardiovascular Health: Timing and Route Matter
Cardiovascular disease becomes increasingly important as women age.
The question should not be reduced to:
“Does estrogen prevent heart attacks?”
That is too simplistic.
We need to consider:
-
when therapy begins
-
baseline vascular health
-
route of estrogen administration
-
insulin resistance
-
blood pressure
-
smoking
-
lipid and lipoprotein profile
-
inflammation
-
body composition
-
family history
ELITE provides evidence that estradiol's vascular effects differ depending on how soon after menopause therapy is initiated.
ESTHER demonstrates that the thrombotic risk of estrogen differs dramatically by route.
A Bayesian meta-analysis of randomized trials involving younger postmenopausal women found a reduction in all-cause mortality associated with hormone therapy, while WHI long-term analyses also demonstrate that age at initiation materially influences the interpretation of outcomes.
This is why the simplistic message that “hormones are bad for the heart” does not withstand scrutiny.
The physiology is more complicated.
HRT and Bone Health: Don't Wait for the Fracture
Many menopausal symptoms eventually get better.
Osteoporosis can quietly worsen for decades.
Estrogen deficiency accelerates bone loss, particularly around the menopausal transition.
That is why a comprehensive hormone evaluation should consider:
-
DEXA bone density
-
fracture history
-
family history
-
vitamin D
-
calcium intake
-
protein intake
-
resistance exercise
-
muscle mass
-
medications
-
thyroid function
-
sex hormones
Randomized trials demonstrate that transdermal estradiol can preserve or increase bone mineral density.
The patient may come in because she cannot sleep.
But good preventive medicine asks what is happening to her skeleton too.
What About Women Who Had a Hysterectomy?
A woman who has undergone hysterectomy may still experience profound hormone decline.
A hysterectomy removes the uterus.
It does not necessarily remove the ovaries.
If the ovaries remain, hormone production may continue for a period of time, although ovarian function can still decline with age.
If the ovaries were removed, the hormonal change can be abrupt.
Women without a uterus do not need progesterone solely for endometrial protection because there is no endometrium to protect.
But our approach is not based solely on whether a uterus exists.
We consider the woman's full physiology, symptoms, sleep, hormonal pattern, and treatment goals.
Early or Surgical Menopause Deserves Special Attention
A woman who loses ovarian function at 38 is not physiologically equivalent to a woman who undergoes natural menopause at 52.
She may face many additional years of estrogen deficiency during a period when her body would ordinarily have been exposed to ovarian hormones.
That has implications for:
-
bone
-
vaginal tissue
-
sexual health
-
quality of life
-
cardiovascular physiology
-
overall health
For women with premature ovarian insufficiency, surgical menopause, or unusually early menopause, hormone restoration deserves particularly serious consideration when no contraindication exists.
Do Laboratory Tests Matter?
Yes.
But they are tools—not the patient.
Depending on the situation, we may evaluate:
-
estradiol
-
progesterone
-
total testosterone
-
free or calculated testosterone
-
SHBG
-
FSH
-
DHEA-S
-
thyroid markers
-
insulin and glucose metabolism
-
lipid and lipoprotein markers
-
vitamin D
-
additional metabolic markers
The interpretation depends partly on where the woman is in the menopausal transition and how hormones are being administered.
Hormone measurements during perimenopause can fluctuate substantially.
Testing after hormone therapy begins must also account for:
-
route
-
timing
-
dose
-
pharmacokinetics
Our goal is not to “treat the lab.”
The laboratory helps us understand the physiology.
FSH: A Useful Signal of Estrogenic Feedback
FSH deserves special mention.
The pituitary produces follicle-stimulating hormone in response to ovarian feedback.
When estradiol production falls, the pituitary often responds by increasing FSH.
This makes FSH a useful physiologic signal when evaluating menopausal hormone status.
Just as TSH reflects pituitary feedback to thyroid hormone signaling, FSH can provide insight into how the hypothalamic-pituitary-ovarian axis is responding to estrogen availability.
It should not be interpreted in isolation, particularly during perimenopause when values can fluctuate.
But it can add useful context to symptoms and estradiol measurements.
Why We Don't Chase the Highest Possible Hormone Level
Restoration does not mean excess.
The goal of BHRT is not:
“More estrogen is better.”
“More testosterone is better.”
“Get every level to the top of the range.”
That is not physiologic medicine.
The objective is to restore a healthy female hormonal environment while monitoring response and avoiding excessive exposure.
Too much estrogen can produce:
-
breast tenderness
-
fluid retention
-
bleeding
-
headaches
Too much progesterone can cause:
-
excessive sedation
-
fatigue
-
bloating
Too much testosterone can cause:
-
acne
-
oily skin
-
unwanted hair growth
-
scalp hair changes
-
voice changes
-
other androgenic effects
Optimization requires both replacing what is missing and knowing when enough is enough.
Hormones Are Not a Substitute for Metabolic Health
Our functional approach to hormone replacement does not mean hormones explain everything.
A woman can have beautifully optimized estradiol and testosterone and still feel terrible if she has:
-
insulin resistance
-
hypothyroidism
-
iron deficiency
-
vitamin deficiencies
-
sleep apnea
-
chronic inflammation
-
excessive alcohol intake
-
inadequate protein
-
severe stress
-
loss of muscle mass
-
a sedentary lifestyle
Likewise, a woman may work extremely hard on lifestyle and still struggle because profound hormone deficiency has changed her physiology.
These are not competing explanations.
The best outcomes usually come from addressing both.
Who Should Consider a BHRT Evaluation?
A woman should consider a comprehensive hormone evaluation when she notices a meaningful change in her health or function, particularly during her 40s, 50s, or after surgical menopause.
Reasons may include:
-
hot flashes
-
night sweats
-
persistent sleep disruption
-
loss of libido
-
vaginal dryness
-
painful intercourse
-
urinary changes
-
unexplained mood changes
-
brain fog
-
declining exercise recovery
-
changes in body composition
-
muscle loss
-
worsening bone density
-
menstrual changes
-
symptoms beginning after hysterectomy or oophorectomy
-
a general feeling that “something changed”
You do not have to diagnose your own hormone deficiency before asking for an evaluation.
That is what the evaluation is for.
Who Needs More Caution?
Hormone replacement requires individualized medical assessment.
Particular caution or specialist evaluation may be necessary in women with histories involving:
-
hormone-sensitive malignancy
-
unexplained vaginal bleeding
-
active thromboembolic disease
-
certain clotting disorders
-
significant liver disease
-
prior stroke or cardiovascular disease
-
other complex medical conditions
The correct response to these situations is not always an automatic yes or an automatic no.
It is careful risk stratification and shared decision-making.
The Functional Medicine Difference: Treat the Woman, Not the Menopause
A standard symptom-based approach often asks:
“How can we make this hot flash stop?”
A functional and integrative approach asks:
“What changed physiologically, what systems are being affected, and how can we restore healthy function?”
That means considering estrogen, progesterone, and testosterone together with:
-
thyroid
-
insulin
-
cortisol and stress physiology
-
cardiovascular risk
-
bone density
-
body composition
-
nutrition
-
exercise
-
sleep
-
gut health
-
inflammation
The hormones do not operate independently.
Neither should the treatment plan.
The Bottom Line: Women Should Not Have to Accept Hormone Deficiency as “Just Aging”
Menopause is natural.
That does not mean every consequence of hormone loss should automatically be accepted without treatment.
Declining estrogen, progesterone, and testosterone can influence far more than menstrual cycles.
For the appropriately selected woman, bioidentical hormone replacement therapy can be used to restore hormonal physiology toward healthy premenopausal levels, improve quality of life, and address important consequences of hormone decline.
Our preferred approach emphasizes:
Bioidentical estradiol rather than non-bioidentical estrogen formulations.
Non-oral estrogen delivery rather than oral estrogen.
Bioidentical progesterone rather than synthetic progestins.
Recognition that testosterone is an important female hormone and may deserve replacement when clinically appropriate.
Systemic restoration when systemic hormone deficiency exists rather than treating every symptom in isolation.
Vaginal estrogen when local therapy is beneficial—but with the understanding that local estrogen does not substitute for systemic hormone restoration when systemic deficiency is the larger problem.
And most importantly:
Individualization.
There is no single hormone program that is right for every woman.
The best treatment starts by understanding where you are now, what has changed, what your hormones are doing, what your long-term health risks are, and what you want your health to look like over the next several decades.
At Revolution Health & Wellness, hormone replacement is not simply about treating hot flashes.
It is about helping women maintain health, function, strength, sexual health, bone health, metabolic health, and quality of life as they move through menopause and beyond.
If you have symptoms that could be related to hormonal decline—even if you have been told that they are “normal for your age”—a comprehensive hormone evaluation can help determine whether estrogen, progesterone, testosterone, or another aspect of your physiology deserves attention.
You may not need every hormone.
You may not need hormone therapy at all.
But you deserve a thoughtful evaluation that asks more than:
“Are you still having periods?”
The better question is:
“Are your hormones still supporting the health and function you want for the rest of your life?”
Frequently Asked Questions About Bioidentical HRT for Women
What is the best estrogen for hormone replacement?
When systemic estrogen replacement is indicated, our preferred estrogen is bioidentical 17-beta estradiol delivered through a non-oral route. We do not favor oral estrogen because first-pass hepatic metabolism changes its physiologic effects and is associated with greater thrombotic risk. The ESTHER study demonstrated increased VTE risk with oral estrogen but not transdermal estrogen.
Why not just use vaginal estrogen?
Vaginal estrogen is excellent for local vaginal and urinary symptoms. However, if a woman has systemic estrogen deficiency, local therapy does not restore systemic estrogen physiology throughout the brain, bone, cardiovascular system, skin, muscle, and other tissues. It can be used alone when the problem is local or alongside systemic therapy when appropriate.
What progesterone do you recommend with estrogen?
Our focus is bioidentical micronized progesterone, not synthetic progestins. The distinction matters because observational studies such as E3N have demonstrated markedly different breast-cancer associations between micronized progesterone and several synthetic progestins.
Can progesterone improve sleep?
It can for some women. Progesterone metabolites interact with GABA-A signaling, and randomized-trial meta-analysis has found improvements in several sleep outcomes with micronized progesterone, particularly in postmenopausal women.
Should women take testosterone?
Not automatically. Testosterone is a normal female hormone, and the strongest randomized evidence supports physiologic testosterone replacement for postmenopausal women with persistent hypoactive sexual desire disorder.
Does testosterone help libido?
Yes, in appropriately selected postmenopausal women. Randomized trials show improvements in desire, arousal, orgasmic function, pleasure, responsiveness, and sexual distress when testosterone is used in doses designed to approximate physiologic premenopausal female concentrations.
Does BHRT cause breast cancer?
That question cannot be answered accurately by treating every form of hormone therapy as identical. Breast-cancer associations differ according to the estrogen regimen, progesterone molecule, duration, patient characteristics, and other factors. WHI and E3N data clearly demonstrate different outcomes with different hormone combinations.
Can I use HRT if I still have periods?
Potentially. Perimenopausal women can develop significant hormonal symptoms years before their final menstrual period. Treatment should be individualized based on symptoms, menstrual patterns, hormone physiology, medical history, and risk.
Is the goal simply to get rid of menopause symptoms?
Not in our approach. Symptom relief matters, but our broader goal is restoring healthy physiology when hormone deficiency is contributing to dysfunction. That includes considering bone health, sexual health, metabolism, body composition, sleep, cardiovascular health, and long-term quality of life.
Scientific References
-
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study. Circulation.2007;115(7):840-845. doi:10.1161/CIRCULATIONAHA.106.642280.
-
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. International Journal of Cancer. 2005;114(3):448-454. doi:10.1002/ijc.20710.
-
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment.2008;107(1):103-111. doi:10.1007/s10549-007-9523-x.
-
Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020;324(4):369-380. doi:10.1001/jama.2020.9482.
-
Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine. 2016;374:1221-1231. doi:10.1056/NEJMoa1505241.
-
Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. Review of KEEPS findings.
-
Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study. PLoS Medicine. 2015.
-
Nolan BJ, Liang B, Cheung AS. Efficacy of micronized progesterone for sleep: a systematic review and meta-analysis of randomized controlled trial data. Journal of Clinical Endocrinology & Metabolism. 2021;106(4):942-951. doi:10.1210/clinem/dgaa873.
-
Prior JC, Hitchcock CL, et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes: a randomized placebo-controlled trial. Scientific Reports. 2023. doi:10.1038/s41598-023-35826-w.
-
Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603.
-
Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine. 2021;18:849-867.
-
Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomized controlled trial data. Lancet Diabetes & Endocrinology. 2019;7(10):754-766.
-
Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. American Journal of Medicine. 2009;122(11):1016-1022.e1. doi:10.1016/j.amjmed.2009.05.021.
-
Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. Journal of General Internal Medicine. 2004;19(7):791-804.
-
Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstetrics & Gynecology. 2004.
-
Arrenbrecht S, Boermans AJM. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized postmenopausal women: a two-year placebo-controlled trial. Osteoporosis International.2002;13(2):176-183.
-
Murkes D, Lalitkumar PG, Leifland K, et al. Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation in healthy women. Fertility and Sterility. 2011;95(3):1188-1191.
-
Murkes D, Conner P, Leifland K, et al. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulation than oral conjugated equine estrogens/medroxyprogesterone acetate in the breast of healthy women in vivo. Gynecological Endocrinology. 2012;28(Suppl 2):12-15.
-
Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignières B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility. 1995;63(4):785-791.
-
Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertility and Sterility. 1998;69(5):963-969.
-
Prior JC. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366-374.
-
Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. Journal of Osteoporosis. 2010;2010:845180.
-
Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. International Journal of Cancer. 2004;112(2):312-318.
-
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
-
Holtorf K. The bioidentical hormone debate: are bioidentical hormones estradiol, estriol, and progesterone safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgraduate Medicine.2009;121(1):73-85.